• Citer

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

par Loibl, Sibylle;Majewski, Ian IJ;Guarneri, V;Nekljudova, Valentina;Holmes, E;Bria, E;Denkert, Carsten;Schem, Christian;Sotiriou, Christos ;Loi, S.;Untch, M;Conte, P;Bernards, René;Piccart-Gebhart, Martine ;von Minckwitz, G;Baselga, J
Référence Annals of oncology, 29, 10, page (2151)
Publication Publié, 2018-10-01

Article révisé par les pairs

• Accès en ligne
• Détails
• Statistiques

Titre:	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Auteur:	Loibl, Sibylle; Majewski, Ian IJ; Guarneri, V; Nekljudova, Valentina; Holmes, E; Bria, E; Denkert, Carsten; Schem, Christian; Sotiriou, Christos; Loi, S.; Untch, M; Conte, P; Bernards, René; Piccart-Gebhart, Martine; von Minckwitz, G; Baselga, J
Informations sur la publication:	Annals of oncology, 29, 10, page (2151)
Statut de publication:	Publié, 2018-10-01
Sujet CREF:	Cancérologie
	Sciences bio-médicales et agricoles
	Médecine pathologie humaine
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdx803
	info:pii/4986930
	info:pmid/29701763